|
|
|
|
An increased risk of cancer has been reported in patients treated with azathioprine.To assess the long-term risk of neoplasia in azathioprine- treated multiple sclerosis(MS)patient,we conducted a case-control study using the Lyon Multiple Sclerosis Database.The results are suggestive of a dose-response relationship with no significant risk during the first years of treatment and a possible increased risk after about 10 years of continuous therapy.Further studies are needed to better assess the risk- benefit ratio of azathioprine in MS. |
|